Blog
Whatever Happened to Hair Cloning?
For decades, hair cloning has been described as the ultimate answer to baldness: take a few healthy follicles, multiply them and create an almost unlimited supply of replacement hair. A new pilot program in Guatemala suggests that regenerative hair restoration is moving forward—but the science is not yet delivering what most people imagine when they hear the word “cloning.”
The Promise That Refused to Die
Hair cloning has been “a few years away” for more than 20 years. Companies have launched ambitious research programs, reported encouraging laboratory results and then quietly disappeared. Yet the central idea remains irresistible: instead of redistributing a limited supply of donor hair, why not manufacture more of it?
A New Milestone in Guatemala
In March 2026, the British biotechnology company HairClone announced that it had begun early clinical testing in Guatemala City. The company has constructed a cell-manufacturing laboratory inside a private hospital, close to the Schambach Hair Clinic, where the experimental procedures are being performed. HairClone says its manufacturing system was transferred from the United Kingdom and validated under Good Manufacturing Practice conditions. (HairClone, March 2026.)
Human Testing Changes the Conversation

This is important because hair-regeneration research has spent years trapped between promising laboratory experiments and practical human treatment. HairClone has now crossed that boundary. Cells taken from human follicles are being multiplied and returned to patients, with changes in hair growth, appearance and cellular activity being monitored.
But Is This Really Hair Cloning?
Not in the popular sense. HairClone is not yet manufacturing thousands of complete new follicles for implantation into a bald scalp. Its immediate objective is more modest: to use multiplied dermal papilla cells to rescue existing follicles that are becoming progressively smaller.
The Tiny Cells That Control Hair
Dermal papilla cells sit near the base of the follicle and help regulate hair growth, shaft size and the hair cycle. HairClone removes healthy donor follicles, isolates these specialized cells, grows millions of them in the laboratory and injects them into thinning areas of the patient’s scalp.
Rejuvenation Comes Before Replacement
The injected cells are intended to influence miniaturizing follicles so that they once again produce thicker, more visible hairs. HairClone describes this as “follicle rejuvenation.” If it works reliably, it could become valuable for people with early or moderate pattern hair loss who still have weakened follicles capable of being rescued.
A Bald Scalp Is a Harder Target

The treatment may be less useful where hair loss is advanced and functioning follicles have largely disappeared. Restoring hair to a completely bald area would probably require follicle neogenesis—the creation of complete new follicles capable of becoming established in the scalp, producing correctly oriented shafts and repeating natural growth cycles.
HairClone Acknowledges the Difference
HairClone’s own scientific information makes this distinction unusually clear. The company says clinically useful hair multiplication still faces significant technical, regulatory and financial obstacles and is unlikely to become a practical treatment in the near future. Its present clinical program is therefore better understood as regenerative follicle-cell therapy than unlimited hair cloning. (HairClone FAQ, 2026.)
The Guatemala program is an important step toward regenerative hair treatment. It is not yet proof that new human follicles can be cloned on demand.
This Is Testing—not Proof
HairClone announced in March that its first volunteers had been selected. Its subsequently updated information says treatments have begun and that local patients will be followed while the procedure is optimized. However, no clinical results have yet been published.
The Missing Numbers Matter
HairClone has not publicly disclosed the number of people treated, the cell doses used, changes in hair count or diameter, the frequency of adverse events or the duration of any improvement. There are also no published standardized before-and-after photographs or peer-reviewed patient results.
Not Yet a Conventional Trial
HairClone describes the Guatemala work as “early clinical testing,” rather than a completed controlled clinical trial. Its own FAQ explains that this stage does not use a fixed protocol, allowing researchers to alter the product, patient selection or procedure as they learn from each treatment.
Flexibility Has a Price
This adaptive approach can help researchers determine the best dose, injection depth and patient profile before committing to a large trial. But a changing protocol, small patient group and absence of a control group make it difficult to determine whether an apparent improvement was caused by the treatment.
Formal Trials Must Follow
HairClone says international clinical trials will be required after the treatment system has been optimized. Those studies will need predetermined endpoints, adequate participant numbers, controls, consistent photography and long-term follow-up. Until those results exist, effectiveness remains an informed possibility—not an established fact.
South Korea Moves Into the Race

HairClone is not alone. South Korean biotechnology company Epibiotech is studying EPI-001, another therapy made from a patient’s own dermal papilla cells. Its Phase I/IIa study is registered as NCT07618195 and is designed to enroll 42 people with androgenetic alopecia. (ClinicalTrials.gov, 2026.)
A More Conventional Test
The first part of the EPI-001 study evaluates dose and safety. The second randomly assigns participants in a two-to-one ratio to receive either EPI-001 or placebo. Investigators plan to measure hair count, hair diameter, clinical photographs and patient and expert assessments for as long as 48 weeks.
No Winner Yet
The Epibiotech study provides a more conventional framework for determining whether cultured dermal papilla cells produce a meaningful improvement. However, it is still an early-stage trial, and no completed efficacy results are available. Neither HairClone nor Epibiotech has yet shown that its treatment can consistently deliver a cosmetically significant result.
Why Has Progress Been So Slow?
A follicle is not simply a strand of hair with a root. It is a miniature organ made from interacting epithelial cells, dermal papilla cells, stem cells, pigment-producing cells, nerves, blood vessels and supporting tissue. These components must communicate correctly and organize themselves in three dimensions.
Cells Forget Their Job
One of the largest obstacles is that human dermal papilla cells change when multiplied in ordinary laboratory culture. They may reproduce successfully but progressively lose the molecular signals that make them capable of directing hair formation.
Aging Happens in the Dish
Research published in 2025 found that senescent, or biologically aged, cells accumulate when human dermal papilla cells are expanded. Removing some of these senescent cells restored aspects of their hair-inducing activity in experimental follicle-reconstitution tests. The finding was encouraging, but it remained mechanistic and preclinical—not evidence of successful cosmetic restoration in patients. (Cell Proliferation, 2025.)
Japan Finds a Missing Ingredient
Another important advance arrived from Japan in 2026. Researchers affiliated with OrganTech identified a third supporting mesenchymal cell population that appears necessary for adult epithelial stem cells and dermal papilla cells to form a fully functioning follicle structure in laboratory culture.
Two Cell Types Were Not Enough
Earlier reconstructed follicles could begin to form a hair bulb but frequently failed to mature, grow downward and produce a shaft. When the researchers added the newly identified supporting cells in the correct three-dimensional arrangement, regenerated follicles formed shafts and showed more complete follicular development. (Biochemical and Biophysical Research Communications, 2026.)
A Breakthrough—with a Mouse-Sized Limitation
The OrganTech work helps explain why earlier follicle-engineering attempts repeatedly stalled. However, the successful structures were produced from adult mouse whisker cells. Repeating the process reliably with human scalp cells—and then manufacturing enough follicles for treatment—remains a much larger challenge.
Direction Matters as Much as Growth
A future treatment must do more than produce hair. New follicles must be inserted at the correct depth and angle, survive transplantation, connect with surrounding tissue and produce hairs with appropriate thickness, color, texture and direction. A follicle that grows sideways, curls beneath the skin or produces only a fine colorless hair has little cosmetic value.
One Growth Cycle Proves Very Little
Hair follicles naturally alternate through growth, transition, resting and shedding phases. A laboratory-created follicle must survive and produce replacement shafts through repeated cycles over many years. Even convincing short-term growth would not establish permanent restoration.
Hair Banking Sells Tomorrow Today
While developing its treatment, HairClone offers a commercial follicle-banking service. Approximately 100–120 follicles are removed using follicular unit excision and cryopreserved for possible future use. The argument is that cells banked today may be younger and more biologically active than cells collected years later.
Preservation Is Real—Future Use Is Not Assured
Cryopreservation is an established method of storing living biological material at extremely low temperatures. HairClone says the follicles remain the patient’s property and may provide cells for multiple future treatments. But preservation does not prove that the eventual treatment will work, receive regulatory approval or remain compatible with the cells being stored.
“No Downtime” Goes Too Far
Hair-banking promotions sometimes describe the extraction as a 30-minute procedure with no downtime. FUE is generally minor, and most people resume normal activities quickly. Nevertheless, removing 120 follicles creates approximately 120 small wounds and can involve bleeding, scabbing, redness, tenderness, swelling, infection, altered sensation and small permanent scars. “Minimal downtime” would be more accurate.
Preferred Pricing Has No Fixed Value
Some clinics are offering “preferred pricing” on a future HairClone treatment to patients who bank follicles before a deadline. Unless the discount, expiration date and eventual treatment price are specified in writing, the offer has no measurable financial value. A percentage reduction on a treatment with no established price or availability remains a promise, not a saving.
Ask Who Protects the Follicles
Before paying, consumers should ask who legally holds the tissue, what annual fees apply, whether those charges can rise and what happens if HairClone, the clinic or the storage facility closes. They should also determine whether the follicles can be transferred to another qualified laboratory and whether any future discount survives such a transfer.
Regulation Will Take Time
No cultured dermal papilla cell treatment or engineered hair-follicle therapy is FDA-approved for hair loss in the United States. The FDA notes that regenerative products made from a patient’s own cells may still require regulatory oversight when the cells are substantially processed or used in a different biological way. (FDA, June 2021.)
Guatemala Is Not FDA Approval
HairClone chose Guatemala partly because locally regulated autologous cell treatments can be handled similarly to transplants. That makes early treatment possible there, but it does not establish approval in the United States, Britain or Europe. Each jurisdiction will require evidence supporting manufacturing quality, safety and efficacy.
Hope Has Finally Become an Experiment
For years, hair cloning existed mainly in laboratory reports, corporate presentations and hopeful predictions. HairClone’s Guatemala program and Epibiotech’s registered study bring follicle-cell therapy into genuine human investigation. That deserves attention.
The Headline Still Runs Ahead of the Science
The honest conclusion is neither that hair cloning has failed nor that it has arrived. Follicle rejuvenation is entering a credible experimental phase. True production of large numbers of new, permanent, cosmetically useful human follicles remains preclinical.
So, Whatever Happened to Hair Cloning?
It became more scientifically realistic—and less simple than its name suggested. Researchers are learning that hair cannot merely be copied. A living follicle must be reconstructed as a functioning miniature organ.
The Dream Is Alive—but Still in the Laboratory
Hair cloning may eventually transform hair restoration, particularly for people with limited donor hair or advanced baldness. The latest developments justify cautious optimism, not a treatment reservation. The next decisive moment will not be another press release. It will be independently reviewable human data showing safe, durable and cosmetically meaningful hair growth.